{"id":"reiferon-retard","safety":{"commonSideEffects":[{"rate":"50-90","effect":"Flu-like symptoms (fever, chills, fatigue)"},{"rate":"30-70","effect":"Headache"},{"rate":"25-60","effect":"Myalgia"},{"rate":"10-50","effect":"Neutropenia"},{"rate":"5-30","effect":"Thrombocytopenia"},{"rate":"10-40","effect":"Depression/mood changes"},{"rate":"5-20","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1165342","moleculeType":"Small molecule","molecularWeight":"354.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon alfa-2a binds to type I interferon receptors on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral and antiproliferative genes. The retard (sustained-release) formulation extends the half-life, allowing for less frequent dosing while maintaining therapeutic interferon levels. This mechanism makes it effective against chronic viral infections and certain malignancies.","oneSentence":"Reiferon retard is a long-acting formulation of interferon alfa-2a that activates innate and adaptive immune responses to inhibit viral replication and tumor cell growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:04:30.953Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C"},{"name":"Chronic hepatitis B"},{"name":"Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas)"}]},"trialDetails":[{"nctId":"NCT02027493","phase":"NA","title":"Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV","status":"COMPLETED","sponsor":"National Liver Institute, Egypt","startDate":"2009-02","conditions":"Hepatitis C, Chronic","enrollment":46},{"nctId":"NCT01896609","phase":"PHASE4","title":"Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population","status":"UNKNOWN","sponsor":"MinaPharm Pharmaceuticals","startDate":"2013-06","conditions":"Chronic Hepatitis c","enrollment":300},{"nctId":"NCT01276756","phase":"PHASE2, PHASE3","title":"Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"Cairo University","startDate":"2010-12","conditions":"Chronic Hepatitis c","enrollment":100},{"nctId":"NCT01649245","phase":"PHASE4","title":"Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C","status":"UNKNOWN","sponsor":"MinaPharm Pharmaceuticals","startDate":"2012-08","conditions":"Chronic Hepatitis C","enrollment":5000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pegylated interferon α 2a"],"phase":"marketed","status":"active","brandName":"Reiferon retard","genericName":"Reiferon retard","companyName":"MinaPharm Pharmaceuticals","companyId":"minapharm-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Reiferon retard is a long-acting formulation of interferon alfa-2a that activates innate and adaptive immune responses to inhibit viral replication and tumor cell growth. Used for Chronic hepatitis C, Chronic hepatitis B, Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}